Drug Trial Radar · NCT05710692
Study to Evaluate the Safety, PK, PD, and Efficacy of PRX-102 in Japanese Patients With Fabry Disease
Last checked: Nov 19, 2026Latest source record: Mar 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
16
Planned (sponsor's estimate)
Start
Aug 1, 2023
Primary completion
Oct 2027
Study completion Aug 2029
Sponsor
- Lead sponsor
- Chiesi Farmaceutici S.p.A.Industry
- Sponsor type
- Industry
- Collaborators
- ICON plc
- First posted
- Feb 2, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 13 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of this study is to evaluate the safety and efficacy of pegunigalsidase alfa in Japanese patients (adults and adolescents) affected by Fabry disease. It is planned of a total of approximately 16 male and female Fabry disease patients between the ages of 13 and 70 years to be part of the study. The study is conducted in Japan.
Conditions
- Fabry Disease
Interventions
PRX-102 1 mg/kg every 2 weeksDrug
PRX-102 1 mg/kg every 2 weeks
PRX-102 2 mg/kg every 4 weeksDrug
PRX-102 2 mg/kg every 4 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment Emergent Adverse Events (TEAEs)Time frame: 12 Months, 24 Months and through study completion (an average of 4.5 years)
- Incidence of Infusion Related Reactions (IRRs)Time frame: 12 Months, 24 Months and through study completion (an average of 4.5 years)
- Incidence of Injection site reactions (ISRs)Time frame: 12 Months, 24 Months and through study completion (an average of 4.5 years)
- Change of laboratory tests' resultsTime frame: 12 Months, 24 Months and through study completion (an average of 4.5 years)
- Change in in body weight in kilogramsTime frame: 12 Months, 24 Months and through study completion (an average of 4.5 years)
- Change in height in centimetersTime frame: 12 Months, 24 Months and through study completion (an average of 4.5 years)
- Change in Tanner stageTime frame: 12 Months, 24 Months and through study completion (an average of 4.5 years)
- Change from baseline of 12-lead ECG quantitative parameters: Mean Heart Rate, PR Interval, QRS Duration, QT Interval, QTc Interval, and ST SegmentTime frame: 12 Months, 24 Months and through study completion (an average of 4.5 years)
- Incidence of treatment-emergent Anti-Drug Antibodies (ADAs)Time frame: 12 Months, 24 Months and through study completion (an average of 4.5 years)
- ADA status change from baselineTime frame: 12 Months, 24 Months and through study completion (an average of 4.5 years)
- Incidence of premedication use at each visit and change of infusion premedications from baselineTime frame: 12 Months, 24 Months and through study completion (an average of 4.5 years)
- Change from baseline of Maximum plasma concentration (Cmax), pharmacokinetic parameterTime frame: Assessments will be done over three two-week periods, starting at Baseline (Week 0), V7 (Week 12), and V27 (Week 52)
- Change from baseline of Time to maximum plasma concentration (tmax), pharmacokinetic parameterTime frame: Assessments will be done over three two-week periods, starting at Baseline (Week 0), V7 (Week 12), and V27 (Week 52)
- Change from baseline of Area under the plasma concentration-time curve from time 0 to time t (AUC0 t), pharmacokinetic parameterTime frame: Assessments will be done over three two-week periods, starting at Baseline (Week 0), V7 (Week 12), and V27 (Week 52)
- Change from baseline of Area under the curve from time 0 to 2 weeks (AUC0-2wk), pharmacokinetic parameterTime frame: Assessments will be done over three two-week periods, starting at Baseline (Week 0), V7 (Week 12), and V27 (Week 52)
- Change from baseline of Area under the curve from time 0 to infinity (AUC0-∞), pharmacokinetic parameterTime frame: Assessments will be done over three two-week periods, starting at Baseline (Week 0), V7 (Week 12), and V27 (Week 52)
- Change from baseline of Terminal half-life (t1/2), pharmacokinetic parameterTime frame: Assessments will be done over three two-week periods, starting at Baseline (Week 0), V7 (Week 12), and V27 (Week 52)
- Change from baseline of Area under the curve over a dosing interval (AUCτ), pharmacokinetic parameterTime frame: Assessments will be done over three two-week periods, starting at Baseline (Week 0), V7 (Week 12), and V27 (Week 52)
- Change from baseline of Observed drug concentration at the end of the dosing interval (Cτ), pharmacokinetic parameterTime frame: Assessments will be done over three two-week periods, starting at Baseline (Week 0), V7 (Week 12), and V27 (Week 52)
- Change from baseline of Clearance (Cl), pharmacokinetic parameterTime frame: Assessments will be done over three two-week periods, starting at Baseline (Week 0), V7 (Week 12), and V27 (Week 52)
- Change from baseline of Volume of distribution (Vz), pharmacokinetic parametersTime frame: Assessments will be done over three two-week periods, starting at Baseline (Week 0), V7 (Week 12), and V27 (Week 52)
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
Asahikawa Medical University Hospital
Asahikawa, Japan · Recruiting
Niigata University Medical & Dental Hospital
Niigata, Japan · Recruiting
National Hospital Organization Okayama Medical Center
Okayama, Japan · Not yet recruiting
Fukuoka University Chikushi Hospital
Chikushino-shi, Fukuoka, Japan · Withdrawn
Tohoku University Hospital
Sendai, Miyagi, Japan · Recruiting
University of the Ryukyu Hospital
Nishihara, Okinawa, Japan · Recruiting
Osaka University Hospital
Suita, Osaka, Japan · Recruiting
Juntendo University Hospital, 3-1-3 Hongo, Bunkyo-ku, Tokyo
Bunkyo-ku, Tokyo, Japan · Recruiting
Tokyo Jikei University Hospital
Minato-ku, Tokyo, Japan · Recruiting
Keio University Hospital
Shinjuku-ku, Tokyo, Japan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.